Support teaching, research, and patient care.
Dr. Anand Veeravagu is Associate Professor of Neurosurgery and Associate Professor of Orthopedic Surgery, by courtesy, and Director of Minimally Invasive NeuroSpine Surgery here at Stanford. Dr. Veeravagu is board certified and is focused on advancing minimally invasive surgical techniques for diseases of the spine and cares for patients with a wide range of spinal disorders. Dr. Veeravagu is the Team Neurosurgeon for the San Francisco 49ers Football Team. Dr. Veeravagu graduated from the Johns Hopkins University Biomedical Engineering program with a focus on spinal cord injury and regeneration. Committed to medical device development, neuroregeneration, and non-invasive imaging he accepted a position to complete his MD at the Stanford University School of Medicine. While a medical student, Dr. Veeravagu worked with neurosurgery and the molecular imaging program to develop novel, non-invasive imaging tools and treatments for malignant neoplasms of central nervous system. Dr. Veeravagu subsequently completed his neurosurgical residency at Stanford University. As a resident, Dr. Veeravagu was appointed by the President of the United States as a White House Fellow in 2012, serving as Special Assistant to Secretary of Defense Leon Panetta and Chuck Hagel to guide Department of Defense Policy on traumatic brain injury, spinal cord injury, and mental health treatment for the United States military. One of 14 people from around the nation to be selected, Dr. Veeravagu served as a speech writer, national security advisor, and health consultant directly to the Secretary of Defense. After completion of his neurosurgical residency, Dr. Veeravagu was awarded the prestigious Neurosurgical Research and Education Foundation Post-Residency Clinical Fellowship Grant and completed his fellowship training in minimally invasive and complex deformity spine at Stanford University with both neurosurgical and orthopaedic training. Dr. Veeravagu also completed a clinical scholar rotation at the University of Miami Miller School of Medicine focused on endoscopic and robotic spine surgery. Dr. Veeravagu’s research efforts are focused on the utilization of large national databases to assess cost, quality, and effectiveness of various treatment algorithms as well as predictive analytics. Dr. Veeravagu is also an author and writes about current events, health policy, and public health-related topics for the San Francisco Chronicle, The Daily Beast, The BBC, and the Huffington Post.
The focus of my laboratory is to utilize precision medicine techniques to improve the diagnosis and treatment of neurologic conditions. From traumatic brain injury to spinal scoliosis, the ability to capture detailed data regarding clinical symptoms and treatment outcomes has empowered us to do better for patients. Utilize data to do better for patients, that’s what we do.Stanford Neurosurgical Ai and Machine Learning Labhttp://med.stanford.edu/neurosurgery/research/AILab.html
PET/MRI in the Diagnosis of Chronic Pain
Several studies have implicated involvement of sigma-1 receptors (SR1s) in the generation of
chronic pain, while others are investigating anti SR1 drugs for treatment of chronic pain.
Using [18F]-FTC-146 and positron emission tomography/magnetic resonance imaging (PET/MRI),
the investigators hope to identify the source of pain generation in patients with chronic
pain. The purpose of this study is to compare the uptake of [18F]FTC-146 in healthy
volunteers to that of individuals suffering from chronic pain.
View full details
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow
to the tumor. Combining dexamethasone and thalidomide may kill more cancer cells. It is not
yet known whether dexamethasone is more effective with or without thalidomide in treating
PURPOSE: Randomized phase III trial to determine the effectiveness of dexamethasone with or
without thalidomide in treating patients who have multiple myeloma.
Stanford is currently not accepting patients for this trial.
For more information, please contact SPECTRUM, .